Long, G. V., Dummer, R., Ribas, A., Puzanov, I., Michielin, O., VanderWalde, A., Andtbacka, R. H., Cebon, J., Fernandez, E., Malvehy, J., Olszanski, A. J., Gajewski, T. F., Kirkwood, J. M., Kuznetsova, O., Chen, L., Kaufman, D. R., Chou, J., & Hodi, F. S. (n.d.). a Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). Journal for immunotherapy of cancer, 3, . http://access.bl.uk/ark:/81055/vdc_100136717612.0x000003